

University of Groningen

Hibernating mitochondria, the cool key to cellular protection and transplant optimization

Hendriks, Koen

DOI:
[10.33612/diss.160451743](https://doi.org/10.33612/diss.160451743)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2021

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Hendriks, K. (2021). *Hibernating mitochondria, the cool key to cellular protection and transplant optimization: Mitochondrial aspects of hibernators and non-hibernators in hypothermia*. [Thesis fully internal (DIV), University of Groningen]. University of Groningen. <https://doi.org/10.33612/diss.160451743>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Gasotransmitters in health and disease: a mitochondria-centered view

Koen D.W. Hendriks#
Hanno Maassen#
Peter R. van Dijk
Robert H. Henning
Harry van Goor*
Jan-Luuk Hillebrands*

Authors contributed equally

* Shared senior authorship


Published: *Curr. Opin. Pharmacol.* (2019)
DOI: [10.1016/j.coph.2019.07.001](https://doi.org/10.1016/j.coph.2019.07.001)

6

ABSTRACT

Gasotransmitters have long been recognized to fulfill important roles in homeostasis with disbalances having been linked to various pathologies, including inflammation and cardiovascular diseases. In addition to known pathways mediating the actions of gasotransmitters, the effects of gasotransmitters in regulating mitochondrial function is emerging. Given the fact that mitochondria are key organelles in energy production, formation of reactive oxygen species and apoptosis, they have been recognized as important mediators of preserving health and developing disease. Preserving or restoring mitochondrial function by gasotransmitters may therefore mitigate several diseases. Here we discuss the actions of gasotransmitters, focusing on their role in mitochondrial function and their therapeutic potential.

GRAPHICAL ABSTRACT



INTRODUCTION

Gasotransmitters are small, chemically reactive, short-living molecules that played crucial roles in the development of life. Nitric oxide (NO) and carbon monoxide (CO) are the first described and best-known gasotransmitters, whereas hydrogen sulfide (H₂S) has been discovered more recently. This third gasotransmitter gained more interest nowadays. Given the fact that gasotransmitters diffuse freely across cellular membranes, they are well equipped to regulate a broad range of important cellular functions in various cell types throughout the body. These include cardinal roles in regulating vascular tone¹, neuro-modulation², paracrine cell signaling³ and mitochondrial function. Due to the effect on important cellular functions, a disturbance in gasotransmitter bioavailability is linked to a variety of pathological conditions. The mitochondrion is one of the targeted organelles of gasotransmitters and their actions modulate mitochondrial function, including important features such as adenosine triphosphate (ATP) production, reactive oxygen species (ROS) formation and initiation of the apoptotic cascade, all important mediators in inflammation and disease.

This review provides a concise overview of recent findings of gasotransmitters influencing inflammation, disease, and the role of mitochondria herein. It also explores avenues to target enzyme activity or supply gasotransmitter donors as therapeutic interventions.

GASOTRANSMITTER SYNTHESIS AND BIOAVAILABILITY

NO is formed by the conversion of L-arginine to L-citrulline, an oxidative process regulated by three subtypes of nitric oxide synthases (NOS) with different expression levels in different cells: neuronal (nNOS), endothelial (eNOS) and inducible (iNOS). Within a cell, iNOS and nNOS are mainly cytosolic, but subcellular distributions are described for nNOS⁴. eNOS is membrane bound, to facilitate release of NO to the extracellular environment.

CO is synthesized by conversion of heme to biliverdin through heme oxygenase (HO), an enzyme known to exist in three isoforms: HO-1, HO-2 and HO-3. HO is mainly located in the endoplasmic reticulum (ER), but, similar to NOS, has also been reported to be present in the mitochondria⁵.

H₂S is derived from conversion of cysteine, catalyzed by cystathionine β-synthase (CBS), cystathionine γ-lyase (CSE) and cysteine aminotransferase (CAT), all three mainly located in the cytosol. However, in line with the mitochondrial NO and CO, CBS and CSE translocate to mitochondria during cellular stress such as hypoxia⁶. Additionally, H₂S is produced directly within mitochondria by 3-mercaptopyruvate

sulfur-transferase (3MST), an enzyme located in mitochondria⁷.

Summarizing, the production of gasotransmitters is regulated by different enzymes, of which spatial expression patterns differ within organs and cell types. Of notice, all gasotransmitters can be produced near or inside mitochondria, indicative of an important role in mitochondrial function.




Figure 1. A general overview of the cellular synthesis and bioavailability of gasotransmitters within a cell. 3MST (3-mercaptopyruvate sulfur-transferase), CBS (cystathionine β-synthase), CSE, (cystathionine γ-lyase) and CAT (cysteine aminotransferase) produce H₂S (hydrogen sulfide). HO (heme oxygenase) produces CO (carbon monoxide). NO (Nitric oxide) is produced by NOS (nitric oxide synthase).

GASOTRANSMITTERS IN PHYSIOLOGY AND DISEASE

A plethora of physiological effects of gasotransmitters have been documented over the past decades. For instance, gasotransmitters, both via direct intracellular effects or released in the extracellular space, are known to play an important role in regulation of vascular tone, have capacity of reducing oxidative stress, and induce angiogenesis⁸. More specifically, CO is involved in processes such as regulation of endothelial cell survival and proliferation, protection from ischemia-reperfusion injury (IRI), vasorelaxation and inhibition of pro-inflammatory responses. HO-1 acts as an inflammation neutralizing factor regulated by nuclear-factor-erythroid 2-related factor-2 (Nrf2), as seen in lung inflammation after intestinal IRI⁹. NO

regulates numerous intra- and intercellular processes such as platelet aggregation, endothelial adhesion of leukocytes and relaxation of smooth muscle cells. Moreover, elevated NO levels, upon nuclear-factor-kappa B (NF-κB) activation and signal-transducer-and-activator-of-transcription-1α (STAT-1α) stimulated iNOS activation, represents an important component in the inflammatory response¹⁰. Excess production of NO, leading to nitrosative stress, is correlated with the severity of liver disease in mice¹¹. In contrast, the anti-inflammatory action of NO is revealed in iNOS-knockout high-fat-diet fed mice, that show an increased inflammation leading to liver fibrosis¹². These concentration-dependent opposing effects stress the requirement of strict regulation of NO production.

H₂S has important anti-inflammatory and antioxidant characteristics, and causes relaxation of blood vessels¹³. H₂S protects endothelial cells from lipopolysaccharide (LPS)-induced inflammation by blocking NF-κB transactivation¹⁴. In addition, exogenous H₂S treatment decreased inflammation and IRI following intestinal ischemia, whereas eNOS knockout mice were not protected by exogenous H₂S, suggesting that H₂S exerts protective effects via eNOS¹⁵. NADPH oxidase (Nox), a mitochondrial source of ROS, is identified as a key-signaling pathway responsible for the increased inflammatory response of macrophages in vitro and in septic mice^{16,17}, which could be ameliorated by endogenous H₂S.

Reduced bioavailability of gasotransmitters and subsequent biological impact has been demonstrated in several disorders such as vascular pathology¹⁸, aging¹⁹ and aging-related pathologies²⁰, renal pathology²¹ and diabetes²². These associations suggest causality between alternated gasotransmitter bioavailability and disease pathogenesis.

The various pathways in which gasotransmitters are involved in disease and inflammation become of even more interest when looking at mitochondrial dysfunction, for example in sepsis. David et al. demonstrated lower ATP levels, overproduction of NO and mitochondrial dysfunction in skeletal muscle biopsies of septic patients²³. Using H₂S and CO, potentiation of mitochondria could preserve tissue function during sepsis, as recently reviewed by Reitsema et al²⁴. The authors suggested various future perspectives on therapeutic interventions to increase exogenous and endogenous H₂S production, to specifically inhibit iNOS and to stimulate HO-1 activity, in order to target mitochondrial pathways in sepsis and inflammation.

A schematic overview of some of the involved pathways is given in figure 2.




Figure 2. A schematic overview of some of the diseases related pathways gasotransmitters are involved in. All three gasotransmitters, H₂S (hydrogen sulfide), CO (carbon monoxide) and NO (nitric oxide) show mitigating effects in a variety of diseases.

MITOCHONDRIAL ASPECTS OF GASOTRANSMITTERS

Mitochondria, often simply referred to as ‘the powerhouse of the cell’ as they represent the main source of energy using oxidative phosphorylation, also fulfil important regulatory and signaling processes. In oxidative phosphorylation, these cell organelles oxidize substrates using their electron transport chain (ETC; or respiratory chain) comprising five complexes cooperating to build up a proton gradient, which is used to drive the ATP synthase. Gasotransmitters are involved in the regulation of this process, supporting normal physiology.

NO, CO and H₂S all reduce the ETC activity via inhibition of cytochrome c oxidase (COX) in a reversible, fast-acting and dose-dependent manner²⁵. Thereby, gasotransmitters are suggested to preserve normal ETC function. Indeed, administration of NO and CO protected mitochondria during hemorrhagic shock²⁶ and upregulation of HO-1 normalized mitochondrial function and decreases ROS formation in IRI²⁷. Also, H₂S protects the ETC by different mechanisms, as extensively described previously²⁸. In line, CSE knockout mice are more susceptible to cerebral IRI compared to controls; which could be restored using exogenous

H₂S²⁹. Interestingly, on the contrary to NO and CO, H₂S can act as hydrogen donor and functions as substrate for mitochondrial respiration³⁰.

In contrast, a high-dose treatment with CO, NO or H₂S can almost completely inhibit mitochondrial activity, especially H₂S showed potential to induce a safe metabolic suppression: a hypometabolic state^{31,32}. This hibernation-like state has shown to be protective to IRI, as occurs in e.g. organ transplantation³³.

Besides direct effects on mitochondrial function, gasotransmitters play an important role in (mitochondria-derived) ROS scavenging. Especially NO is a potent antioxidant by virtue of its fast reaction with hydroxyl radicals, superoxides and lipid peroxides³⁴. Exogenous H₂S administration protected cardiac tissue from ROS damage in a myocardial injury rat model³⁵.

In addition to the direct scavenging potential, gasotransmitters are also important in the activation of scavenging pathways, such as Nrf2 and glutathione (GSH). Kelch-like-ECH-associated-protein-1 (Keap1) serves as a negative regulator of Nrf2, during stress free physiology, Keap1 binds to Nrf2 in the cytoplasm and promotes degradation of Nrf2. Cellular stress, such as provoked by ROS, inactivates Keap1 and therefore stabilizes Nrf2, allowing translocation to the nucleus and activation of its target: the antioxidant-response-element (ARE)^{36,37}. Alternatively, H₂S can promote the Keap1-dependent Nrf2 stabilization, which helps Nrf2 translocation into the nucleus³⁸. Indeed, exogenous NaHS administration in a diabetic stressed rat model resulted in increased nuclear Nrf2 levels, activation of superoxide dismutase (SOD) and limited apoptosis³⁹. Besides increasing GSH production, H₂S is believed to redistribute GSH into the mitochondria to directly scavenge the mitochondrial-produced superoxides⁴⁰, advocating the interest in the mitochondrial located H₂S production. CO exposure in transplanted rat lungs protected against apoptosis, likely via increased SOD activity and decreased ROS damage⁴¹.

Another important pathway that gasotransmitters are involved in is the opening of the mitochondrial permeability transition pore (mPTP). By mechanisms not yet fully understood, channels can be formed in the inner membrane of mitochondria: the mPTP. Full opening of the mPTP, induced by several factors among which excessive ROS and calcium-overload, results in a loss of mitochondrial membrane potential and oxidative phosphorylation, mitochondrial swelling and a burst of ROS, eventually leading to necrosis or apoptosis⁴². Exogenous H₂S has shown to inhibit apoptosis via blocking mPTP opening and cytochrome c (cyt c) release⁴³. Next to mPTP opening, apoptosis can be activated by the Bcl2-family, cyt c release and caspase activation. Both NO and CO are known to suppress the Bcl2-family and caspase activation^{44,45}.

Altogether, gasotransmitters have an important role in the cellular energetic state and apoptosis by regulating several mitochondrial- and ROS-related actions, as outlined in figure 3.




Figure 3. A simplified overview of the interactions between gasotransmitters and mitochondria.

ETC = electron transport chain, ROS = reactive oxygen species, GSH = glutathione.

TREATMENT PERSPECTIVES

Exogenous administration of gasotransmitters is an emerging therapeutic option. The oldest and most used donor is the acute NO donor nitroglycerin, causing vasodilation and acute pain relief during angina pectoris. Another clinically relevant NO donor in current use is sodium nitroprusside (SNP), also playing an important role in vasorelaxation. Based on these successes, several NO donors were synthesized, among which NO donors coupled to other medication, such as NO-NSAID⁴⁶. Additionally, more downstream NO-interfering drugs were tested, such as the highly specific phosphodiesterase 5 (PDE5) inhibitor sildenafil⁴⁷. Sildenafil treatment showed an increased activity of the NO and cGMP pathway and protection against oxidative damage and apoptosis in diseases such as diabetes⁴⁸ and cardiovascular dysfunction⁴⁹. In contrast, most recent findings in pregnant women with fetal growth restriction revealed detrimental effects of sildenafil treatment⁵⁰. In line with the functions of CO, carbon monoxide-releasing-molecules (CORMs) have shown anti-apoptotic, anti-inflammatory, and antioxidant effects⁵¹. Widely used under experimental conditions are H₂S donors NaHS and Na₂S. These sodium salts lead to a fast and high concentration of H₂S. Ideally to induce a hypometabolic state³², but not suitable for precise and sustained

administration. A potential alternative can be found in sodium thiosulfate (STS). STS showed positive effects on hypertension and renal injury⁵². The potential of STS on reducing cardiac ischemia is now being clinically tested.

Recently, slower H₂S donating molecules have been synthesized, such as GYY4137, AP39 or DATS-MSN, which show promising results in IRI by exploiting the protective properties of H₂S. Sun X et al. suggested that DATS-MSN shows superior anti-apoptotic, antioxidant and anti-inflammatory abilities over NaHS⁵³. AP39, a mitochondrial targeted H₂S donor, has shown very potent protective effects in an organ transplantation model⁵⁴. Interestingly, also (ROS)-triggered H₂S donors⁵⁵ and slow-releasing NO/H₂S hybrid molecules are invented⁵⁶ with promising effects against heart failure⁵⁷.

CONCLUSION

Gasotransmitters play a vital role in various diseases, with a central role for its effects on mitochondria. H₂S, CO and NO all have their specific roles in maintaining accurate mitochondrial function or inducing mitochondrial distress and show a broad variety of potential therapeutic properties: influencing ETC activity, direct scavenging, activation of scavenging pathways and suppression of apoptosis. These effects qualify gasotransmitters as potential efficacious drugs and, recently, have led to the synthesis of long-lasting and slow releasing donors for therapeutic use. Although promising results have been obtained in experimental disease models, sufficient clinical studies are lacking. This urges the need for more extensive research and maybe even new compounds. A mitochondrial targeted combination of H₂S-NO-CO donor is an attractive concept to protect mitochondria from noxious insults; whether this concept is actually applicable remains to be seen in the near future.

Acknowledgements

We like to thank Maaïke van der Meulen for designing the artworks.

REFERENCES

1. Gheibi S, Jeddi S, Kashfi K, Ghasemi A: Regulation of vascular tone homeostasis by NO and H₂S: Implications in hypertension. *Biochem Pharmacol.* 2018, 149:42-59.
2. Shefa U, Kim D, Kim MS, Jeong NY, Jung J: Roles of Gasotransmitters in Synaptic Plasticity and Neuropsychiatric Conditions. *Neural Plast.* 2018, doi: 10.1155/2018/1824713.
3. Mustafa AK, Gadalla MM, Snyder SH: Signaling by gasotransmitters. *Sci Signal.* 2009, doi:10.1126/scisignal.268re2.
4. Zhou L, Zhu DY: Neuronal nitric oxide synthase: structure, subcellular localization, regulation, and clinical implications. *Nitric Oxide.* 2009, 4:223-30.
5. Waltz PK, Kautza B, Luciano J, Dyer M, Stolz DB, Loughran P, Neal MD, Sperry JL, Rosengart MR, Zuckerbraun BS: Heme Oxygenase-2 Localizes to Mitochondria and Regulates Hypoxic Responses in Hepatocytes. *Oxid Med Cell Longev.* 2018, doi: 10.1155/2018/2021645.
6. Teng H, Wu B, Zhao K, Yang G, Wu L, Wang R: Oxygen-sensitive mitochondrial accumulation of cystathionine β -synthase mediated by Lon protease. *Proc Natl Acad Sci U S A.* 2013, 31:12679-84.
7. Shibuya N, Tanaka M, Yoshida M, Ogasawara Y, Togawa T, Ishii K, Kimura H: 3-Mercaptopyruvate Sulfurtransferase Produces Hydrogen Sulfide and Bound Sulfane Sulfur in the Brain. *Antioxid. Redox Signal* 2009, 11(4):703-14.
8. Wu D, Hu Q, Zhu D: An Update on Hydrogen Sulfide and Nitric Oxide Interactions in the Cardiovascular System. *Oxid Med Cell Longev.* 2018, doi: 10.1155/2018/4579140.
9. Meng QT, Cao C, Wu Y, Liu HM, Li W, Sun Q, Chen R, Xiao YG, Tang LH, Jiang Y: Ischemic post-conditioning attenuates acute lung injury induced by intestinal ischemia-reperfusion in mice: role of Nrf2. *Lab Invest.* 2016, 96:1087-10.
10. Kleinert H, Pautz A, Linker K, Schwarz PM: Regulation of the expression of inducible nitric oxide synthase. *Eur J Pharmacol.* 2004, 500(1-3):255-66.
11. Salamone F, Galvano F, Cappello F, Mangiameli A, Barbagallo I, Li Volti G: Silibinin modulates lipid homeostasis and inhibits nuclear factor kappa B activation in experimental nonalcoholic steatohepatitis. *Transl Res.* 2012, 159(6):477-86.
12. Nozaki Y, Fujita K, Wada K, Yoneda M, Kessoku T, Shinohara Y, Imajo K, Ogawa Y, Nakamuta M, Saito S: Deficiency of iNOS-derived NO accelerates lipid accumulation-independent liver fibrosis in non-alcoholic steatohepatitis mouse model. *BMC Gastroenterol.* 2015, 1;15:42.
13. Hedegaard ER, Gouliava A, Winther AK, Arcanjo DD, Aalling M, Renaltan NS, Wood ME, Whiteman M, Skovgaard N, Simonsen U: Involvement of Potassium Channels and Calcium-Independent Mechanisms in Hydrogen Sulfide-Induced Relaxation of Rat Mesenteric Small Arteries. *J Pharmacol Exp Ther.* 2016, 356(1):53-63.
14. Bourque C, Zhang Y, Fu M, Racine M, Greasley A, Pei Y, Wu L, Wang R, Yang G: H₂S protects lipopolysaccharide-induced inflammation by blocking NF κ B transactivation in endothelial cells. *Toxicol Appl Pharmacol.* 2018, 338:20-29.
15. Jensen AR, Drucker NA, Khanekis, Ferkowicz MJ, Markel TA: Hydrogen sulfide improves intestinal recovery following ischemia by endothelial nitric oxide-dependent mechanisms. *Am J Physiol Gastrointest Liver Physiol.* 2017, 312(5): G450–G456.
16. Liu W, Wu H, Chen L, Wen Y, Kong X, Gao WQ: Park7 interacts with p47(phox) to direct NADPH oxidase-dependent ROS production and protect against sepsis. *Cell Res* 2015, 25: 691-706.
17. Wang XL, Pan LL, Long F, Wu WJ, Yan D, Xu P, Liu SY, Qin M, Jia WW, Liu XH, Zu YZ: Endogenous Hydrogen Sulfide Ameliorates NOX4 Induced Oxidative Stress in LPS-Stimulated Macrophages and Mice. *Cell Physiol Biochem* 2018, 47:458–474.
18. Bibli SI, Hu J, Sigala F, Wittig I, Heidler J, Zukunft S, Tsilimigras DI, Randriamboavonjy V, Wittig J, Kojonazarov B et al.: Cystathionine γ Lyase Sulfhydrates the RNA Binding Protein Human Antigen R to Preserve Endothelial Cell Function and Delay Atherogenesis. *Circulation* 2019, 139(1):101-114.
19. Perridon BW, Leuvenink HG, Hillebrands JL, van Goor H, Bos EM: The role of hydrogen sulfide in aging and age-related pathologies. *Aging (Albany NY)* 2016, 8(10):2264-2289.
20. Shefa U, Yeo SG, Kim MS, Song IO, Jung J, Jeong NY, Huh Y: Role of Gasotransmitters in Oxidative Stresses, Neuroinflammation, and Neuronal Repair. *BioMed Research International* 2017, 2017:1689341.
21. Koning AM, Frenay AS, Leuvenink HGD, van Goor H: Hydrogen sulfide in renal physiology, disease and transplantation – The smell of renal protection. *Nitric Oxide* 2015, 30;46:37-49.
22. van den Born JC, Hammes HP, Greffrath W, van Goor H, Hillebrands JL: Gasotransmitters in Vascular Complications of Diabetes. *Diabetes* 2016, 65(2): 331-345.
23. Brealey D, Brand M, Hargreaves I, Heales S, Land J, Smolenski R, Davies NA, Cooper CE, Singer M: Association between mitochondrial dysfunction and severity and outcome of septic shock. *Lancet* 2002, 360(9328):219-23.
24. Reitsema VA, Star BS, de Jager VD, van Meurs M, Henning RH, Bouma HR: Metabolic Resuscitation Strategies to Prevent Organ Dysfunction in Sepsis. *Antioxidants & Redox Signaling* 2019, <https://doi.org/10.1089/ars.2018.7537>.
25. Hartmann C, Nussbaum B, Calzia E, Radermacher P, Wepler M: Gaseous Mediators and Mitochondrial Function: The Future of Pharmacologically Induced Suspended Animation?. *Front Physiol.* 2017, 2017;8:691.
26. Haugaa H, Gómez H5, Maberry DR, Holder A, Ogundele O, Quintero AM, Escobar D, Tønnessen TI, Airgood H, Dezfulian C et al.: Effects of inhalation of low-dose nitrite or carbon monoxide on post-reperfusion mitochondrial function and tissue injury in hemorrhagic shock swine. *Crit Care.* 2015, 22;19:184.
27. Chen D, Jin Z, Zhang J, Jiang L, Chen K, He X, Song Y, Ke J, Wang Y: HO-1 Protects against Hypoxia/Reoxygenation-Induced Mitochondrial Dysfunction in H9c2 Cardiomyocytes. *PLoS One* 2016, 11(5):e0153587.
28. Wetzel MD, Wenke JC: Mechanisms by which hydrogen sulfide attenuates muscle function following ischemia-reperfusion injury: effects on Akt signaling, mitochondrial function, and apoptosis. *J Transl Med.* 2019, 17(1):33.
29. Wen JY, Wang M, Li YN, Jiang HH, Sun XJ, Chen ZW: Vascular Protection of Hydrogen Sulfide on Cerebral Ischemia/Reperfusion Injury in Rats. *Front Neurol.* 2018, 19;9:779.
30. Helmy N, Prip-Buus C, Vons C, Lenoir V, Abou-Hamdan A, Guedouari-Bounihi H, Lombès A, Bouillaud F: Oxidation of hydrogen sulfide by human liver mitochondria. *Nitric Oxide* 2014, 15;41:105-12.
31. Blackstone E, Morrison M, Roth MB: H₂S induces a suspended animation-like state in mice. *Science* 2005, 22;308(5721):518.
32. Dugbartey GJ, Bouma HR, Saha MN, Lobb I, Henning RH, Sener A: A Hibernation-Like State for Transplantable Organs: Is Hydrogen Sulfide Therapy the Future of Organ Preservation? *Antioxid. Redox Signal.* 2018, 28, 1503–1515.
33. Lobb I, Davison M, Carter D, Liu W, Haig A, Gunaratnam L, Sener A: Hydrogen Sulfide Treatment Mitigates Renal Allograft Ischemia-Reperfusion Injury during Cold Storage and Improves Early Transplant Kidney Function and Survival Following Allogeneic Renal Transplantation. *J Urol.* 2015, 194(6):1806-15.
34. Wink DA, Miranda KM, Espey MG, Pluta RM, Hewett SJ, Colton C, Vitek M, Feelisch M, Grisham MB: Mechanisms of the antioxidant effects of nitric oxide. *Antioxid. Redox Signal.* 2001, 3(2):203-213.
35. Geng B, Chang L, Pan C, Qi Y, Zhao J, Pang Y, Du J, Tang C: Endogenous hydrogen sulfide regulation of myocardial injury induced by isoproterenol. *Biochem Biophys Res Commun.* 2004, 318(3):756-63.
36. Suzuki T, Yamamoto M. Molecular basis of the Keap1-Nrf2 system. *Free Radic Biol Med.* 2015, 88(Pt B):93-100.

37. Raghunath A, Sundarraj K, Nagarajan R, Arfuso F, Bian J, Kumar AP, Sethi G, Perumal E: Antioxidant response elements: Discovery, classes, regulation and potential applications. *Redox Biology* 2018, 17:297-314.
38. Guo C, Liang F, Shah Masood W, Yan X: Hydrogen sulfide protected gastric epithelial cell from ischemia/reperfusion injury by Keap1 s-sulfhydration, MAPK dependent anti-apoptosis and NF- κ B dependent anti-inflammation pathway. *European Journal of Pharmacology* 2014, 725:70-8.
39. Liu J, Wu J, Sun A, Sun Y, Yu X, Liu N, Dong S, Yang F, Zhang L, Zhong X et al.: Hydrogen sulfide decreases high glucose/palmitate-induced autophagy in endothelial cells by the Nrf2-ROS-AMPK signaling pathway. *Cell Biosci.* 2016, 6:33.
40. Kimura Y, Goto Y, Kimura H: Hydrogen sulfide increases glutathione production and suppresses oxidative stress in mitochondria. *Antioxid Redox Signal* 2010, 12(1):1-13.
41. Song R1, Kubo M, Morse D, Zhou Z, Zhang X, Dauber JH, Fabisiak J, Alber SM, Watkins SC, Zuckerbraun BS et al.: Carbon monoxide induces cytoprotection in rat orthotopic lung transplantation via anti-inflammatory and anti-apoptotic effects. *Am J Pathol.* 2003, 163(1):231-42.
42. Rottenberg H, Hoek JB: The path from mitochondrial ROS to aging runs through the mitochondrial permeability transition pore. *Aging Cell.* 2017;16(5):943-955.
43. Li H, Zhang C, Sun W, Li L, Wu B, Bai S, Li H, Zhong X, Wang R, Wu L et al: Exogenous hydrogen sulfide restores cardioprotection of ischemic post-conditioning via inhibition of mPTP opening in the aging cardiomyocytes. *Cell Biosci.* 2015, 30:5:43.
44. Olson SY, Garbán HJ: Regulation of apoptosis-related genes by nitric oxide in cancer. *Nitric Oxide* 2008, 19(2):170-6
45. Wang X, Wang Y, Kim HP, Nakahira K, Ryter SW, Choi AM: Carbon monoxide protects against hyperoxia-induced endothelial cell apoptosis by inhibiting reactive oxygen species formation. *J Biol Chem.* 2007, 282(3):1718-26.
46. Miller MR, Megson IL: Recent developments in nitric oxide donor drugs. *Br J Pharmacol.* 2007, 151(3):305-21.
47. Francis SH, Busch JL, Corbin JD, Sibley D: cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action. *Pharmacol Rev.* 2010, 62(3):525-63.
48. Ebrahimi F, Shafaroodi H, Asadi S, Nezami BG, Ghasemi M, Rahimpour S, Hashemi M, Doostar Y, Dehpour AR: Sildenafil decreased cardiac cell apoptosis in diabetic mice: reduction of oxidative stress as a possible mechanism. *Physiol Pharmacol.* 2009, 87(7):556-64.
49. Itani N, Skeffington KL, Beck C, Giussani DA: Sildenafil therapy for fetal cardiovascular dysfunction during hypoxic development: studies in the chick embryo. *J Physiol.* 2017, 1;595(5):1563-1573
50. Groom KM, Ganzevoort W, Alfirevic Z, Lim K, Papageorghiou AT: Clinicians should stop prescribing sildenafil for fetal growth restriction (FGR): comment from the STRIDER Consortium. *Ultrasound Obstet Gynecol.* 2018, 52(3):295-296.
51. Kim HH, Choi S: Therapeutic Aspects of Carbon Monoxide in Cardiovascular Disease. *Int J Mol Sci.* 2018, 19(8):2381.
52. Snijder PM, Frenay AR, Koning AM, Bachtler M, Pasch A, Kwakernaak AJ, van den Berg E, Bos EM, Hillebrands JL, Navis G: Sodium thiosulfate attenuates angiotensin II-induced hypertension, proteinuria and renal damage. *Nitric Oxide* 2014, 15;42:87-98.
53. Sun X, Wang W, Dai J, Jin S, Huang J, Guo C, Wang C, Pang L, Wang Y: A Long-Term and Slow-Releasing Hydrogen Sulfide Donor Protects against Myocardial Ischemia/Reperfusion Injury. *Sci Rep.* 2017, 14;7(1):3541.
54. Juriasingani S, Akbari M1, Chan JY, Whiteman M, Sener A. H2S supplementation: A novel method for successful organ preservation at subnormothermic temperatures. *Nitric Oxide* 2018, 1;81:57-66.
55. Zhao Y, Pluth MD: Hydrogen Sulfide Donors Activated by Reactive Oxygen Species. *Angew Chem Int Ed Engl.* 2016, 14;55(47):14638-14642.
56. Hu Q, Wu D, Ma F, Yang S, Tan B, Xin H, Gu X, Chen X, Chen S, Mao Y et al.: Novel Angiogenic Activity and Molecular Mechanisms of ZYZ-803, a Slow-Releasing Hydrogen Sulfide-Nitric Oxide Hybrid Molecule. *Antioxid Redox Signal* 2016, 10;25(8):498-514.
57. Wu D, Hu Q, Xiong Y, Zhu D, Mao Y, Zhu YZ: Novel H2S-NO hybrid molecule (ZYZ-803) promoted synergistic effects against heart failure. *Redox Biol.* 2018, 15:243-252.

ABBREVIATIONS

3MST	3-mercaptopyruvate sulfur-transferase
ARE	antioxidant response element
CAT	cysteine aminotransferase
CBS	cystathionine β -synthase
CO	carbon monoxide
CORMs	CO-releasing molecules
COX	cytochrome C oxidase
CSE	cystathionine γ -lyase
Cyt c	cytochrome c
ER	endoplasmic reticulum
ETC	electron transport chain
GSH	glutathione
H ₂ S	hydrogen sulfide
HO	heme oxygenase
IRI	ischemia-reperfusion injury
Keap1	kelch-like ECH-associated protein 1
LPS	lipopolysaccharide
mPTP	mitochondrial permeability transition pore
NF- κ B	nuclear factor kappa B
NO	nitric oxide
NOS	nitric oxide synthases
Nox	NADPH oxidase
Nrf2	nuclear-factor-E2-related factor-2
PDE5	phosphodiesterase 5
ROS	reactive oxygen species
SNP	sodium nitroprusside
STAT-1 α	signal transducer and activator of transcription-1 α
STS	sodium thiosulfate
TNF- α	tumor necrosis factor- α